THE Myopia Meeting, presented by CRO (Clinical & Refractive Optometry) Journal and Review of Myopia Management, took place at the International Center in Mississauga on Sunday, November 6th. This full-day event was the first of its kind in Canada and included lectures and workshops from leading researchers, clinicians, and industry partners.
Dr. Debbie Jones, BSc, FCOptom started off the first COPE-accredited continuing education lecture by acknowledging that Canada is a world leader in myopia management; Canada has endorsed the World Council of Optometry’s resolution to make evidence-based myopia management the standard of care.
She then provided a review of the various therapies available and discussed what the future of myopia control might look like.
Leading Canadian Experts Lend Advice
Dr. Vishakha Thakrar, OD, FSLS, FAAO talked about the practical applications of myopia management using her experience in private practice, such as the importance of having a supportive and well-trained team.
Dr. Langis Michaud, OD, MSc discussed myopia as a failure in emmetropization, the importance of the quality of the visual signal in myopia control management, and ongoing research. He detailed how he tailors treatment to each individual patient and gave the audience some of his very own clinical pearls.
Dr. Stephanie Ramdass OD, MS, MBA finished off the lectures for the day by presenting case examples and her tips for troubleshooting myopia management.
Leading Myopia Players Present Options
Key manufacturers displayed their latest in myopia control technology through workshops and table displays in an adjacent exhibit room.
HOYA’s MiYOSMART lenses use Defocus Incorporated Multiple Segments (D.I.M.S) Technology and have been available in Canada since 2020. Their most recent data shows that the myopia control effect was sustained over six years.
EssilorLuxottica is committed to supporting ECPs in their management of myopia. As one of the founding members of the Global Myopia Awareness Coalition (GMAC), they aim to increase public awareness of myopia as a treatable disease, with campaign expansions into Canada coming soon. EssilorLuxottica has also created training programs for ECPs and their staff, and developed Stellest spectacle lenses as an effective myopia control therapy which uses Highly Aspheric Lenslet Target (HALT) Technology.
CooperVision’s MiSight 1 day lenses use ActivControl Technology (dual focus) in their Proclear material. Their most recent data (Part 3 of their 7-year study) show that there is no rebound effect with MiSight. This is the longest continuous soft contact lens study for myopia management.
Johnson & Johnson Vision’s ACUVUE Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management have received approval from Health Canada. Made of the same material as ACUVUE OASYS 1-Day, the Abiliti lens has the same benefits in a smaller diameter for pediatric eyes. These lenses use RingBoost Technology, which allows for a stronger treatment power while maintaining visual quality.
Attendees of THE Myopia Meeting were able to obtain a comprehensive look into the best practices of myopia management today.
Hopefully this event is the first of many!
Dr. Jaclyn Chang graduated from the University of Waterloo (UW) with an Honours Bachelor of Science in Biomedical Sciences before continuing at Waterloo to complete her Doctor of Optometry degree. She is currently a practicing optometrist in Toronto.
Dr. Chang is committed to sharing information and bringing new resources to her colleagues. As a student, she sat on the Board of Trustees for the American Optometric Student Association, organizing events to connect students with industry. She was the Co-Founder/Co-President of the award-winning UW Advancement of Independent Optometry Club, the first club at UW dedicated to private practice optometry. Dr. Chang is also a passionate writer, who aims to make information accessible and easily digestible to her colleagues. She has published in Optometry & Vision Science and has contributed to Foresight and Optik magazine.